Loading ...

Fast insight into nanotechnology

Access easily searchable nanoscience data, synthesis methods and literature

erlotinib/cyclopamine-encapsulating irinotecan/riboflavin-containing PEG-based polymer nanoparticles colloid

Based on

1 Articles
2016 Most recent source

Composition

1

erlotinib/cyclopamine mixture

ET/CP
Type Complex Compound
Formula
Role core
2

irinotecan-modified polyethyleneglycol-based biphenyl-4-carboxylic acid derivative

BCA-C6-PEG-S-Ir polymer
Type Polymer
Formula
Role layer
3

riboflavin-modified polyethyleneglycol-based biphenyl-4-carboxylic acid derivative

BCA-C6-PEG-R polymer
Type Polymer
Formula
Role layer

Properties

General physical and chemical properties

Property Value Nanomaterial Variant Source
colloidal stability

More information/entries available to subscribers only.

Or, view sample content

Applications

Characterization

Method Nanomaterial Variant Source
dynamic light scattering

More information/entries available to subscribers only.

Or, view sample content

Biological effects

Biological system Test details Nanomaterial Variant Source
female BALB/c nude mice bearing with MCF-7 xenograft tumor

More information/entries available to subscribers only.

Or, view sample content

Preparation

Method 1

Type: Physical formation
Source:
Starting materials
  • irinotecan-modified polyethyleneglycol-based biphenyl-4-carboxylic acid derivative
  • erlotinib
  • cyclopamine
See all (4)
  1. 2Iks8JOpRVg06NOCwuNU3QvCICcJmqpdf1et6Mcutgaopu0lrUs7txHAanJZ3U7QbdS
Product

erlotinib/cyclopamine-encapsulating irinotecan/riboflavin-containing PEG-based polymer nanoparticles colloid

Size: not specified

Medium/Support: none

Method 2

Type: Physical formation
Source:
Starting materials
Product

erlotinib/cyclopamine-encapsulating irinotecan/riboflavin-containing PEG-based polymer nanoparticles colloid

Hydrodynamic diameter: ~ 40 nm

Medium: Dulbecco's modified Eagle medium containing fetal bovine serum

Support: none

References

Full content is available to subscribers only

To view content please choose from the following:

We use cookies to improve your experience with our site. More information

Sign up for a free trial